- Home
- DHY vs IMRX Comparison
DHY vs IMRX Comparison
Compare DHY & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHY
- IMRX
- Stock Information
- Founded
- DHY 1998
- IMRX 2008
- Country
- DHY United States
- IMRX United States
- Employees
- DHY N/A
- IMRX N/A
- Industry
- DHY Finance/Investors Services
- IMRX Biotechnology: Pharmaceutical Preparations
- Sector
- DHY Finance
- IMRX Health Care
- Exchange
- DHY Nasdaq
- IMRX Nasdaq
- Market Cap
- DHY 220.7M
- IMRX 232.9M
- IPO Year
- DHY N/A
- IMRX 2021
- Fundamental
- Price
- DHY $2.09
- IMRX $8.49
- Analyst Decision
- DHY
- IMRX Strong Buy
- Analyst Count
- DHY 0
- IMRX 4
- Target Price
- DHY N/A
- IMRX $13.00
- AVG Volume (30 Days)
- DHY 569.1K
- IMRX 1.3M
- Earning Date
- DHY 01-01-0001
- IMRX 11-12-2025
- Dividend Yield
- DHY 9.10%
- IMRX N/A
- EPS Growth
- DHY N/A
- IMRX N/A
- EPS
- DHY N/A
- IMRX N/A
- Revenue
- DHY N/A
- IMRX N/A
- Revenue This Year
- DHY N/A
- IMRX N/A
- Revenue Next Year
- DHY N/A
- IMRX N/A
- P/E Ratio
- DHY N/A
- IMRX N/A
- Revenue Growth
- DHY N/A
- IMRX N/A
- 52 Week Low
- DHY $1.77
- IMRX $1.10
- 52 Week High
- DHY $2.08
- IMRX $9.37
- Technical
- Relative Strength Index (RSI)
- DHY 43.26
- IMRX 79.86
- Support Level
- DHY $2.07
- IMRX $5.17
- Resistance Level
- DHY $2.11
- IMRX $9.37
- Average True Range (ATR)
- DHY 0.02
- IMRX 0.78
- MACD
- DHY 0.00
- IMRX 0.31
- Stochastic Oscillator
- DHY 50.00
- IMRX 81.16
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.
About IMRX Immuneering Corporation
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.